UAE, May 12 -- Novo Nordisk announced data on May 13, demonstrating that Wegovy(R) (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from premenopausal years through the menopause transition and beyond.

The findings are based on the STEP-UP clinical weight management trial, the landmark SELECT clinical cardiovascular trial and one large-scale real-world evidence study, all presented at the European Congress on Obesity (ECO) 2026 in Istanbul, Turkey1-3. The studies show that when women with obesity lose weight with semaglutide, they improve their body composition with reduced waist circumference, indicative of less visceral fat, and they also red...